PIVOT-02: A phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-214 and nivolumab in patients with select, locally advanced or metastatic solid tumor malignancies
Adi Diab(Cleveland Clinic), Mario Sznol(Yale University), D. Cho, Michael K. Wong(Roswell Park Comprehensive Cancer Center), Jonathan Zalevsky(Nektar Therapeutics (United States)), Salah-Eddine Bentebibel(The University of Texas MD Anderson Cancer Center), I. Gergel(Nektar Therapeutics (United States)), Brendan D. Curti(Providence Portland Medical Center), Ute Hoch(University of Arizona), Igor Puzanov(Roswell Park Comprehensive Cancer Center), Michael J. Imperiale(University of Michigan), Cara Haymaker(The University of Texas MD Anderson Cancer Center), Chantale Bernatchez(BMC Software (United States)), Nizar M. Tannir(The University of Texas MD Anderson Cancer Center), Mary Tagliaferri(Nektar Therapeutics (United States)), Michael E. Hurwitz(Yale University), Patrick Hwu(Moffitt Cancer Center), Harriet M. Kluger(Yale Cancer Center), Sandra Aung(Nektar Therapeutics (United States)), Scott S. Tykodi(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa)
Cited by 5
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k